Mid-Phase Alzheimer’s Failure Sends Neurotrope’s Stock Spiraling Downward
Shares in Neurotrope fell 80% after bryostatin-1 performed no better than placebo in patients with moderate-to-severe Alzheimer’s disease. Neurotrope is yet to officially give up on the protein kinase C epsilon modulator, though.
You may also be interested in...
The US FDA’s decision to ask on device adverse event reports whether the device involved had been serviced by a third party could help the agency as well as device makers, says Ricki Chase, compliance practice director at Lachman Consultant Services.
The FDA has almost 30 decision dates coming up before New Year’s Eve, including nearly a dozen novel agents.
Complaint lists host of problems with implementation of the rule that allows states to sponsor programs to import certain prescription drugs from Canada; at least six states have enacted legislation to sponsor these programs.